Boston CEOs point to a rise in funding rounds and M&A deals in late 2025 as evidence that biotech companies are learning to adapt to ongoing challenges rather than being paralyzed by them.
Read More from Bizjournals.com Feed (2025-02-17 17:26:56)
Biotech industry shows signs of recovery as investors return and dealmaking accelerates
